nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP1A2—Clobetasol propionate—psoriasis	0.0702	0.122	CbGbCtD
Citalopram—CYP2B6—Cholecalciferol—psoriasis	0.0417	0.0725	CbGbCtD
Citalopram—CYP1A2—Methoxsalen—psoriasis	0.0369	0.0642	CbGbCtD
Citalopram—CYP2D6—Hydroxyurea—psoriasis	0.0332	0.0578	CbGbCtD
Citalopram—CYP2C19—Cholecalciferol—psoriasis	0.0265	0.0461	CbGbCtD
Citalopram—CYP3A4—Calcitriol—psoriasis	0.0248	0.0433	CbGbCtD
Citalopram—CYP2D6—Cholecalciferol—psoriasis	0.0201	0.035	CbGbCtD
Citalopram—CYP3A4—Methoxsalen—psoriasis	0.0193	0.0336	CbGbCtD
Citalopram—ABCB1—Mycophenolate mofetil—psoriasis	0.0185	0.0322	CbGbCtD
Citalopram—CYP2C19—Prednisone—psoriasis	0.0183	0.032	CbGbCtD
Citalopram—CYP2E1—Dexamethasone—psoriasis	0.0183	0.0318	CbGbCtD
Citalopram—CYP2B6—Dexamethasone—psoriasis	0.018	0.0314	CbGbCtD
Citalopram—CYP2C19—Cyclosporine—psoriasis	0.0174	0.0303	CbGbCtD
Citalopram—ABCB1—Betamethasone—psoriasis	0.0159	0.0277	CbGbCtD
Citalopram—ABCB1—Prednisolone—psoriasis	0.0157	0.0273	CbGbCtD
Citalopram—ABCB1—Hydrocortisone—psoriasis	0.0149	0.0259	CbGbCtD
Citalopram—ABCB1—Prednisone—psoriasis	0.0148	0.0258	CbGbCtD
Citalopram—ABCB1—Cyclosporine—psoriasis	0.014	0.0244	CbGbCtD
Citalopram—CYP2D6—Cyclosporine—psoriasis	0.0132	0.023	CbGbCtD
Citalopram—CYP3A4—Cholecalciferol—psoriasis	0.0128	0.0223	CbGbCtD
Citalopram—CYP2C19—Dexamethasone—psoriasis	0.0115	0.0199	CbGbCtD
Citalopram—CYP3A4—Mycophenolate mofetil—psoriasis	0.0111	0.0193	CbGbCtD
Citalopram—CYP3A4—Triamcinolone—psoriasis	0.0111	0.0193	CbGbCtD
Citalopram—CYP3A4—Betamethasone—psoriasis	0.00952	0.0166	CbGbCtD
Citalopram—CYP3A4—Prednisolone—psoriasis	0.00939	0.0164	CbGbCtD
Citalopram—ABCB1—Dexamethasone—psoriasis	0.00924	0.0161	CbGbCtD
Citalopram—CYP3A4—Hydrocortisone—psoriasis	0.0089	0.0155	CbGbCtD
Citalopram—CYP3A4—Prednisone—psoriasis	0.00887	0.0154	CbGbCtD
Citalopram—CYP2D6—Dexamethasone—psoriasis	0.00871	0.0152	CbGbCtD
Citalopram—CYP3A4—Cyclosporine—psoriasis	0.00841	0.0146	CbGbCtD
Citalopram—ABCB1—Methotrexate—psoriasis	0.00743	0.0129	CbGbCtD
Citalopram—CYP3A4—Dexamethasone—psoriasis	0.00554	0.00964	CbGbCtD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000124	0.00373	CbGpPWpGaD
Citalopram—HRH1—IL-4 Signaling Pathway—NFKBIA—psoriasis	0.000121	0.00366	CbGpPWpGaD
Citalopram—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000118	0.00357	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000118	0.00357	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—IL13—psoriasis	0.000118	0.00355	CbGpPWpGaD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000116	0.00351	CbGpPWpGaD
Citalopram—SLC6A3—Monoamine Transport—TNF—psoriasis	0.000116	0.0035	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—HCAR2—psoriasis	0.000115	0.00347	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—HCAR2—psoriasis	0.000115	0.00346	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—HCAR2—psoriasis	0.000113	0.00341	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000113	0.0034	CbGpPWpGaD
Citalopram—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000111	0.00335	CbGpPWpGaD
Citalopram—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.00011	0.00331	CbGpPWpGaD
Citalopram—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000109	0.0033	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000108	0.00326	CbGpPWpGaD
Citalopram—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000108	0.00325	CbGpPWpGaD
Citalopram—ADRA1A—AMPK Signaling—LEP—psoriasis	0.000105	0.00317	CbGpPWpGaD
Citalopram—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000103	0.00312	CbGpPWpGaD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000103	0.00311	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000101	0.00304	CbGpPWpGaD
Citalopram—HRH1—IL-4 Signaling Pathway—TYK2—psoriasis	9.93e-05	0.003	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—HLA-E—psoriasis	9.82e-05	0.00296	CbGpPWpGaD
Citalopram—CYP1A2—Tryptophan metabolism—CAT—psoriasis	9.58e-05	0.00289	CbGpPWpGaD
Citalopram—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.14e-05	0.00276	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.06e-05	0.00273	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.57e-05	0.00259	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.45e-05	0.00255	CbGpPWpGaD
Citalopram—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.26e-05	0.00249	CbGpPWpGaD
Citalopram—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	8.22e-05	0.00248	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.13e-05	0.00245	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.85e-05	0.00237	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.83e-05	0.00236	CbGpPWpGaD
Citalopram—HRH1—IL-4 Signaling Pathway—NFKB1—psoriasis	7.74e-05	0.00233	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.7e-05	0.00232	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—LEP—psoriasis	7.57e-05	0.00228	CbGpPWpGaD
Citalopram—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	7.56e-05	0.00228	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	7.51e-05	0.00227	CbGpPWpGaD
Citalopram—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.4e-05	0.00223	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—IL10—psoriasis	7.35e-05	0.00222	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—IL4—psoriasis	7.15e-05	0.00216	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	7.05e-05	0.00213	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—HLA-B—psoriasis	7e-05	0.00211	CbGpPWpGaD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.99e-05	0.00211	CbGpPWpGaD
Citalopram—HRH1—IL-4 Signaling Pathway—STAT3—psoriasis	6.95e-05	0.0021	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—CCL20—psoriasis	6.9e-05	0.00208	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HCAR2—psoriasis	6.82e-05	0.00206	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	6.59e-05	0.00199	CbGpPWpGaD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.51e-05	0.00196	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—HCAR2—psoriasis	6.5e-05	0.00196	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—HCAR2—psoriasis	6.48e-05	0.00196	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.48e-05	0.00196	CbGpPWpGaD
Citalopram—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.4e-05	0.00193	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—HCAR2—psoriasis	6.38e-05	0.00193	CbGpPWpGaD
Citalopram—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.37e-05	0.00192	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	6.16e-05	0.00186	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—CCL20—psoriasis	5.98e-05	0.0018	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—CCL20—psoriasis	5.96e-05	0.0018	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.92e-05	0.00179	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HCAR2—psoriasis	5.91e-05	0.00178	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	5.91e-05	0.00178	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HCAR2—psoriasis	5.89e-05	0.00178	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—CCL20—psoriasis	5.87e-05	0.00177	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HCAR2—psoriasis	5.8e-05	0.00175	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	5.73e-05	0.00173	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	5.63e-05	0.0017	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.51e-05	0.00166	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.32e-05	0.00161	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	5.23e-05	0.00158	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	5e-05	0.00151	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	4.99e-05	0.00151	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—JUN—psoriasis	4.68e-05	0.00141	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.6e-05	0.00139	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—LEP—psoriasis	4.53e-05	0.00137	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.43e-05	0.00134	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—IFNG—psoriasis	4.32e-05	0.0013	CbGpPWpGaD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.32e-05	0.0013	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	4.29e-05	0.00129	CbGpPWpGaD
Citalopram—ADRA1A—AMPK Signaling—TP53—psoriasis	4.28e-05	0.00129	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—NOS2—psoriasis	4.22e-05	0.00127	CbGpPWpGaD
Citalopram—Pain—Prednisolone—psoriasis	4.21e-05	0.000107	CcSEcCtD
Citalopram—Haemorrhage—Methotrexate—psoriasis	4.21e-05	0.000107	CcSEcCtD
Citalopram—Hepatitis—Methotrexate—psoriasis	4.21e-05	0.000107	CcSEcCtD
Citalopram—Urticaria—Mycophenolate mofetil—psoriasis	4.19e-05	0.000107	CcSEcCtD
Citalopram—Headache—Mycophenolic acid—psoriasis	4.19e-05	0.000107	CcSEcCtD
Citalopram—Decreased appetite—Hydrocortisone—psoriasis	4.18e-05	0.000106	CcSEcCtD
Citalopram—Pharyngitis—Methotrexate—psoriasis	4.18e-05	0.000106	CcSEcCtD
Citalopram—Body temperature increased—Mycophenolate mofetil—psoriasis	4.17e-05	0.000106	CcSEcCtD
Citalopram—Abdominal pain—Mycophenolate mofetil—psoriasis	4.17e-05	0.000106	CcSEcCtD
Citalopram—Urinary tract disorder—Methotrexate—psoriasis	4.16e-05	0.000106	CcSEcCtD
Citalopram—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.15e-05	0.000106	CcSEcCtD
Citalopram—Fatigue—Hydrocortisone—psoriasis	4.15e-05	0.000106	CcSEcCtD
Citalopram—Vision blurred—Prednisone—psoriasis	4.13e-05	0.000105	CcSEcCtD
Citalopram—Urethral disorder—Methotrexate—psoriasis	4.13e-05	0.000105	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.13e-05	0.000105	CcSEcCtD
Citalopram—Pain—Hydrocortisone—psoriasis	4.11e-05	0.000105	CcSEcCtD
Citalopram—Anaphylactic shock—Dexamethasone—psoriasis	4.11e-05	0.000105	CcSEcCtD
Citalopram—Oedema—Dexamethasone—psoriasis	4.11e-05	0.000105	CcSEcCtD
Citalopram—Oedema—Betamethasone—psoriasis	4.11e-05	0.000105	CcSEcCtD
Citalopram—Anaphylactic shock—Betamethasone—psoriasis	4.11e-05	0.000105	CcSEcCtD
Citalopram—Insomnia—Triamcinolone—psoriasis	4.1e-05	0.000104	CcSEcCtD
Citalopram—Infection—Dexamethasone—psoriasis	4.08e-05	0.000104	CcSEcCtD
Citalopram—Infection—Betamethasone—psoriasis	4.08e-05	0.000104	CcSEcCtD
Citalopram—Ill-defined disorder—Prednisone—psoriasis	4.07e-05	0.000104	CcSEcCtD
Citalopram—Paraesthesia—Triamcinolone—psoriasis	4.07e-05	0.000104	CcSEcCtD
Citalopram—Feeling abnormal—Prednisolone—psoriasis	4.06e-05	0.000103	CcSEcCtD
Citalopram—Visual impairment—Methotrexate—psoriasis	4.06e-05	0.000103	CcSEcCtD
Citalopram—Anaemia—Prednisone—psoriasis	4.05e-05	0.000103	CcSEcCtD
Citalopram—Shock—Betamethasone—psoriasis	4.04e-05	0.000103	CcSEcCtD
Citalopram—Shock—Dexamethasone—psoriasis	4.04e-05	0.000103	CcSEcCtD
Citalopram—Dyspnoea—Triamcinolone—psoriasis	4.04e-05	0.000103	CcSEcCtD
Citalopram—Nervous system disorder—Dexamethasone—psoriasis	4.03e-05	0.000103	CcSEcCtD
Citalopram—Nervous system disorder—Betamethasone—psoriasis	4.03e-05	0.000103	CcSEcCtD
Citalopram—Agitation—Prednisone—psoriasis	4.03e-05	0.000103	CcSEcCtD
Citalopram—HTR2C—Signaling Pathways—HCAR2—psoriasis	4.03e-05	0.00122	CbGpPWpGaD
Citalopram—Thrombocytopenia—Betamethasone—psoriasis	4.02e-05	0.000102	CcSEcCtD
Citalopram—Thrombocytopenia—Dexamethasone—psoriasis	4.02e-05	0.000102	CcSEcCtD
Citalopram—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.02e-05	0.00121	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.02e-05	0.00121	CbGpPWpGaD
Citalopram—Tachycardia—Dexamethasone—psoriasis	4.01e-05	0.000102	CcSEcCtD
Citalopram—Tachycardia—Betamethasone—psoriasis	4.01e-05	0.000102	CcSEcCtD
Citalopram—Angioedema—Prednisone—psoriasis	4.01e-05	0.000102	CcSEcCtD
Citalopram—Hypersensitivity—Cyclosporine—psoriasis	3.99e-05	0.000102	CcSEcCtD
Citalopram—Dyspepsia—Triamcinolone—psoriasis	3.99e-05	0.000102	CcSEcCtD
Citalopram—Erythema multiforme—Methotrexate—psoriasis	3.98e-05	0.000101	CcSEcCtD
Citalopram—Nausea—Mycophenolic acid—psoriasis	3.97e-05	0.000101	CcSEcCtD
Citalopram—Hyperhidrosis—Betamethasone—psoriasis	3.97e-05	0.000101	CcSEcCtD
Citalopram—Hyperhidrosis—Dexamethasone—psoriasis	3.97e-05	0.000101	CcSEcCtD
Citalopram—Feeling abnormal—Hydrocortisone—psoriasis	3.96e-05	0.000101	CcSEcCtD
Citalopram—Malaise—Prednisone—psoriasis	3.95e-05	0.000101	CcSEcCtD
Citalopram—CHRM1—Circadian rythm related genes—PPARG—psoriasis	3.95e-05	0.00119	CbGpPWpGaD
Citalopram—Vertigo—Prednisone—psoriasis	3.94e-05	0.0001	CcSEcCtD
Citalopram—Eye disorder—Methotrexate—psoriasis	3.93e-05	0.0001	CcSEcCtD
Citalopram—Gastrointestinal pain—Hydrocortisone—psoriasis	3.93e-05	0.0001	CcSEcCtD
Citalopram—Syncope—Prednisone—psoriasis	3.93e-05	0.0001	CcSEcCtD
Citalopram—Tinnitus—Methotrexate—psoriasis	3.92e-05	9.99e-05	CcSEcCtD
Citalopram—Anorexia—Dexamethasone—psoriasis	3.92e-05	9.97e-05	CcSEcCtD
Citalopram—Anorexia—Betamethasone—psoriasis	3.92e-05	9.97e-05	CcSEcCtD
Citalopram—Urticaria—Prednisolone—psoriasis	3.91e-05	9.96e-05	CcSEcCtD
Citalopram—Cardiac disorder—Methotrexate—psoriasis	3.91e-05	9.95e-05	CcSEcCtD
Citalopram—Fatigue—Triamcinolone—psoriasis	3.9e-05	9.94e-05	CcSEcCtD
Citalopram—HTR2C—GPCR downstream signaling—CCL20—psoriasis	3.9e-05	0.00118	CbGpPWpGaD
Citalopram—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.89e-05	9.9e-05	CcSEcCtD
Citalopram—Asthenia—Cyclosporine—psoriasis	3.88e-05	9.89e-05	CcSEcCtD
Citalopram—Pain—Triamcinolone—psoriasis	3.87e-05	9.86e-05	CcSEcCtD
Citalopram—Loss of consciousness—Prednisone—psoriasis	3.85e-05	9.81e-05	CcSEcCtD
Citalopram—Hypotension—Betamethasone—psoriasis	3.84e-05	9.78e-05	CcSEcCtD
Citalopram—Hypotension—Dexamethasone—psoriasis	3.84e-05	9.78e-05	CcSEcCtD
Citalopram—Pruritus—Cyclosporine—psoriasis	3.83e-05	9.75e-05	CcSEcCtD
Citalopram—Urticaria—Hydrocortisone—psoriasis	3.82e-05	9.73e-05	CcSEcCtD
Citalopram—Angiopathy—Methotrexate—psoriasis	3.82e-05	9.72e-05	CcSEcCtD
Citalopram—Immune system disorder—Methotrexate—psoriasis	3.8e-05	9.68e-05	CcSEcCtD
Citalopram—Body temperature increased—Hydrocortisone—psoriasis	3.8e-05	9.68e-05	CcSEcCtD
Citalopram—Abdominal pain—Hydrocortisone—psoriasis	3.8e-05	9.68e-05	CcSEcCtD
Citalopram—Convulsion—Prednisone—psoriasis	3.8e-05	9.67e-05	CcSEcCtD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.8e-05	0.00115	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NDUFA5—psoriasis	3.79e-05	0.00114	CbGpPWpGaD
Citalopram—Mediastinal disorder—Methotrexate—psoriasis	3.79e-05	9.66e-05	CcSEcCtD
Citalopram—Asthenia—Mycophenolate mofetil—psoriasis	3.79e-05	9.64e-05	CcSEcCtD
Citalopram—Hypertension—Prednisone—psoriasis	3.79e-05	9.64e-05	CcSEcCtD
Citalopram—Chills—Methotrexate—psoriasis	3.78e-05	9.62e-05	CcSEcCtD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.77e-05	0.00114	CbGpPWpGaD
Citalopram—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.74e-05	9.53e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Betamethasone—psoriasis	3.74e-05	9.53e-05	CcSEcCtD
Citalopram—Pruritus—Mycophenolate mofetil—psoriasis	3.73e-05	9.51e-05	CcSEcCtD
Citalopram—Myalgia—Prednisone—psoriasis	3.73e-05	9.51e-05	CcSEcCtD
Citalopram—Arthralgia—Prednisone—psoriasis	3.73e-05	9.51e-05	CcSEcCtD
Citalopram—Feeling abnormal—Triamcinolone—psoriasis	3.73e-05	9.5e-05	CcSEcCtD
Citalopram—Anxiety—Prednisone—psoriasis	3.72e-05	9.47e-05	CcSEcCtD
Citalopram—Alopecia—Methotrexate—psoriasis	3.72e-05	9.47e-05	CcSEcCtD
Citalopram—CYP2E1—Metabolism—NDUFA5—psoriasis	3.72e-05	0.00112	CbGpPWpGaD
Citalopram—Insomnia—Betamethasone—psoriasis	3.72e-05	9.46e-05	CcSEcCtD
Citalopram—Insomnia—Dexamethasone—psoriasis	3.72e-05	9.46e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.71e-05	9.44e-05	CcSEcCtD
Citalopram—Diarrhoea—Cyclosporine—psoriasis	3.7e-05	9.43e-05	CcSEcCtD
Citalopram—Paraesthesia—Dexamethasone—psoriasis	3.69e-05	9.4e-05	CcSEcCtD
Citalopram—Paraesthesia—Betamethasone—psoriasis	3.69e-05	9.4e-05	CcSEcCtD
Citalopram—Discomfort—Prednisone—psoriasis	3.69e-05	9.39e-05	CcSEcCtD
Citalopram—Mental disorder—Methotrexate—psoriasis	3.69e-05	9.39e-05	CcSEcCtD
Citalopram—Malnutrition—Methotrexate—psoriasis	3.66e-05	9.33e-05	CcSEcCtD
Citalopram—Erythema—Methotrexate—psoriasis	3.66e-05	9.33e-05	CcSEcCtD
Citalopram—Hypersensitivity—Prednisolone—psoriasis	3.63e-05	9.24e-05	CcSEcCtD
Citalopram—Dyspepsia—Betamethasone—psoriasis	3.62e-05	9.21e-05	CcSEcCtD
Citalopram—Dyspepsia—Dexamethasone—psoriasis	3.62e-05	9.21e-05	CcSEcCtD
Citalopram—Diarrhoea—Mycophenolate mofetil—psoriasis	3.61e-05	9.2e-05	CcSEcCtD
Citalopram—Urticaria—Triamcinolone—psoriasis	3.6e-05	9.16e-05	CcSEcCtD
Citalopram—Dysgeusia—Methotrexate—psoriasis	3.59e-05	9.14e-05	CcSEcCtD
Citalopram—Body temperature increased—Triamcinolone—psoriasis	3.58e-05	9.12e-05	CcSEcCtD
Citalopram—Dizziness—Cyclosporine—psoriasis	3.58e-05	9.11e-05	CcSEcCtD
Citalopram—Oedema—Prednisone—psoriasis	3.58e-05	9.11e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Prednisone—psoriasis	3.58e-05	9.11e-05	CcSEcCtD
Citalopram—Decreased appetite—Betamethasone—psoriasis	3.57e-05	9.1e-05	CcSEcCtD
Citalopram—Decreased appetite—Dexamethasone—psoriasis	3.57e-05	9.1e-05	CcSEcCtD
Citalopram—Infection—Prednisone—psoriasis	3.55e-05	9.05e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Betamethasone—psoriasis	3.55e-05	9.03e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Dexamethasone—psoriasis	3.55e-05	9.03e-05	CcSEcCtD
Citalopram—Back pain—Methotrexate—psoriasis	3.54e-05	9.03e-05	CcSEcCtD
Citalopram—Hypersensitivity—Hydrocortisone—psoriasis	3.54e-05	9.02e-05	CcSEcCtD
Citalopram—Fatigue—Betamethasone—psoriasis	3.54e-05	9.02e-05	CcSEcCtD
Citalopram—Fatigue—Dexamethasone—psoriasis	3.54e-05	9.02e-05	CcSEcCtD
Citalopram—HTR2C—Signaling by GPCR—CCL20—psoriasis	3.54e-05	0.00107	CbGpPWpGaD
Citalopram—Shock—Prednisone—psoriasis	3.52e-05	8.96e-05	CcSEcCtD
Citalopram—Pain—Dexamethasone—psoriasis	3.51e-05	8.95e-05	CcSEcCtD
Citalopram—Pain—Betamethasone—psoriasis	3.51e-05	8.95e-05	CcSEcCtD
Citalopram—Nervous system disorder—Prednisone—psoriasis	3.51e-05	8.94e-05	CcSEcCtD
Citalopram—Tachycardia—Prednisone—psoriasis	3.49e-05	8.89e-05	CcSEcCtD
Citalopram—HTR2C—Signaling Pathways—TAGAP—psoriasis	3.49e-05	0.00105	CbGpPWpGaD
Citalopram—Dizziness—Mycophenolate mofetil—psoriasis	3.49e-05	8.89e-05	CcSEcCtD
Citalopram—HRH1—Signaling Pathways—HCAR2—psoriasis	3.49e-05	0.00105	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HCAR2—psoriasis	3.48e-05	0.00105	CbGpPWpGaD
Citalopram—Skin disorder—Prednisone—psoriasis	3.48e-05	8.85e-05	CcSEcCtD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	3.46e-05	0.00104	CbGpPWpGaD
Citalopram—Hyperhidrosis—Prednisone—psoriasis	3.46e-05	8.81e-05	CcSEcCtD
Citalopram—Vision blurred—Methotrexate—psoriasis	3.45e-05	8.79e-05	CcSEcCtD
Citalopram—Asthenia—Hydrocortisone—psoriasis	3.45e-05	8.79e-05	CcSEcCtD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.44e-05	0.00104	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.44e-05	0.00104	CbGpPWpGaD
Citalopram—Vomiting—Cyclosporine—psoriasis	3.44e-05	8.76e-05	CcSEcCtD
Citalopram—ADRA1A—Signaling Pathways—HCAR2—psoriasis	3.42e-05	0.00103	CbGpPWpGaD
Citalopram—Rash—Cyclosporine—psoriasis	3.41e-05	8.69e-05	CcSEcCtD
Citalopram—Anorexia—Prednisone—psoriasis	3.41e-05	8.69e-05	CcSEcCtD
Citalopram—Dermatitis—Cyclosporine—psoriasis	3.41e-05	8.68e-05	CcSEcCtD
Citalopram—Pruritus—Hydrocortisone—psoriasis	3.4e-05	8.66e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Methotrexate—psoriasis	3.4e-05	8.66e-05	CcSEcCtD
Citalopram—Headache—Cyclosporine—psoriasis	3.39e-05	8.63e-05	CcSEcCtD
Citalopram—Anaemia—Methotrexate—psoriasis	3.39e-05	8.62e-05	CcSEcCtD
Citalopram—Feeling abnormal—Betamethasone—psoriasis	3.39e-05	8.62e-05	CcSEcCtD
Citalopram—Feeling abnormal—Dexamethasone—psoriasis	3.39e-05	8.62e-05	CcSEcCtD
Citalopram—HRH1—GPCR downstream signaling—CCL20—psoriasis	3.38e-05	0.00102	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—CCL20—psoriasis	3.37e-05	0.00102	CbGpPWpGaD
Citalopram—Gastrointestinal pain—Dexamethasone—psoriasis	3.36e-05	8.56e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Betamethasone—psoriasis	3.36e-05	8.56e-05	CcSEcCtD
Citalopram—Vomiting—Mycophenolate mofetil—psoriasis	3.36e-05	8.55e-05	CcSEcCtD
Citalopram—Hypersensitivity—Triamcinolone—psoriasis	3.34e-05	8.5e-05	CcSEcCtD
Citalopram—Rash—Mycophenolate mofetil—psoriasis	3.33e-05	8.48e-05	CcSEcCtD
Citalopram—Dermatitis—Mycophenolate mofetil—psoriasis	3.33e-05	8.47e-05	CcSEcCtD
Citalopram—ADRA1A—GPCR downstream signaling—CCL20—psoriasis	3.32e-05	0.001	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.31e-05	0.000999	CbGpPWpGaD
Citalopram—Headache—Mycophenolate mofetil—psoriasis	3.31e-05	8.42e-05	CcSEcCtD
Citalopram—Malaise—Methotrexate—psoriasis	3.3e-05	8.41e-05	CcSEcCtD
Citalopram—Vertigo—Methotrexate—psoriasis	3.29e-05	8.38e-05	CcSEcCtD
Citalopram—Diarrhoea—Hydrocortisone—psoriasis	3.29e-05	8.38e-05	CcSEcCtD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.29e-05	0.000992	CbGpPWpGaD
Citalopram—Leukopenia—Methotrexate—psoriasis	3.28e-05	8.35e-05	CcSEcCtD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.28e-05	0.000989	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.27e-05	0.000985	CbGpPWpGaD
Citalopram—Urticaria—Dexamethasone—psoriasis	3.26e-05	8.31e-05	CcSEcCtD
Citalopram—Urticaria—Betamethasone—psoriasis	3.26e-05	8.31e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Prednisone—psoriasis	3.26e-05	8.3e-05	CcSEcCtD
Citalopram—Dizziness—Prednisolone—psoriasis	3.26e-05	8.29e-05	CcSEcCtD
Citalopram—Asthenia—Triamcinolone—psoriasis	3.25e-05	8.27e-05	CcSEcCtD
Citalopram—Abdominal pain—Betamethasone—psoriasis	3.25e-05	8.27e-05	CcSEcCtD
Citalopram—Body temperature increased—Dexamethasone—psoriasis	3.25e-05	8.27e-05	CcSEcCtD
Citalopram—Abdominal pain—Dexamethasone—psoriasis	3.25e-05	8.27e-05	CcSEcCtD
Citalopram—Body temperature increased—Betamethasone—psoriasis	3.25e-05	8.27e-05	CcSEcCtD
Citalopram—Insomnia—Prednisone—psoriasis	3.24e-05	8.24e-05	CcSEcCtD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.23e-05	0.000974	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP2S1—psoriasis	3.23e-05	0.000973	CbGpPWpGaD
Citalopram—Nausea—Cyclosporine—psoriasis	3.21e-05	8.19e-05	CcSEcCtD
Citalopram—Paraesthesia—Prednisone—psoriasis	3.21e-05	8.18e-05	CcSEcCtD
Citalopram—Pruritus—Triamcinolone—psoriasis	3.2e-05	8.16e-05	CcSEcCtD
Citalopram—Cough—Methotrexate—psoriasis	3.2e-05	8.14e-05	CcSEcCtD
Citalopram—Dizziness—Hydrocortisone—psoriasis	3.18e-05	8.1e-05	CcSEcCtD
Citalopram—Convulsion—Methotrexate—psoriasis	3.17e-05	8.08e-05	CcSEcCtD
Citalopram—CYP2E1—Metabolism—CYP2S1—psoriasis	3.16e-05	0.000953	CbGpPWpGaD
Citalopram—Dyspepsia—Prednisone—psoriasis	3.15e-05	8.02e-05	CcSEcCtD
Citalopram—Nausea—Mycophenolate mofetil—psoriasis	3.14e-05	7.98e-05	CcSEcCtD
Citalopram—Chest pain—Methotrexate—psoriasis	3.12e-05	7.94e-05	CcSEcCtD
Citalopram—Arthralgia—Methotrexate—psoriasis	3.12e-05	7.94e-05	CcSEcCtD
Citalopram—Myalgia—Methotrexate—psoriasis	3.12e-05	7.94e-05	CcSEcCtD
Citalopram—Decreased appetite—Prednisone—psoriasis	3.11e-05	7.92e-05	CcSEcCtD
Citalopram—Rash—Prednisolone—psoriasis	3.1e-05	7.91e-05	CcSEcCtD
Citalopram—Dermatitis—Prednisolone—psoriasis	3.1e-05	7.9e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.1e-05	7.89e-05	CcSEcCtD
Citalopram—SLC6A4—Circadian rythm related genes—TP53—psoriasis	3.09e-05	0.000932	CbGpPWpGaD
Citalopram—Fatigue—Prednisone—psoriasis	3.08e-05	7.86e-05	CcSEcCtD
Citalopram—Headache—Prednisolone—psoriasis	3.08e-05	7.86e-05	CcSEcCtD
Citalopram—Discomfort—Methotrexate—psoriasis	3.08e-05	7.85e-05	CcSEcCtD
Citalopram—HRH1—Signaling by GPCR—CCL20—psoriasis	3.07e-05	0.000926	CbGpPWpGaD
Citalopram—Constipation—Prednisone—psoriasis	3.06e-05	7.79e-05	CcSEcCtD
Citalopram—CHRM1—Signaling by GPCR—CCL20—psoriasis	3.06e-05	0.000923	CbGpPWpGaD
Citalopram—Vomiting—Hydrocortisone—psoriasis	3.06e-05	7.79e-05	CcSEcCtD
Citalopram—Rash—Hydrocortisone—psoriasis	3.03e-05	7.72e-05	CcSEcCtD
Citalopram—Dermatitis—Hydrocortisone—psoriasis	3.03e-05	7.71e-05	CcSEcCtD
Citalopram—HRH1—Signaling Pathways—TAGAP—psoriasis	3.03e-05	0.000913	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TAGAP—psoriasis	3.02e-05	0.00091	CbGpPWpGaD
Citalopram—Confusional state—Methotrexate—psoriasis	3.02e-05	7.68e-05	CcSEcCtD
Citalopram—Headache—Hydrocortisone—psoriasis	3.01e-05	7.67e-05	CcSEcCtD
Citalopram—ADRA1A—Signaling by GPCR—CCL20—psoriasis	3.01e-05	0.000908	CbGpPWpGaD
Citalopram—Dizziness—Triamcinolone—psoriasis	2.99e-05	7.63e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Methotrexate—psoriasis	2.99e-05	7.62e-05	CcSEcCtD
Citalopram—Infection—Methotrexate—psoriasis	2.97e-05	7.57e-05	CcSEcCtD
Citalopram—ADRA1A—Signaling Pathways—TAGAP—psoriasis	2.97e-05	0.000896	CbGpPWpGaD
Citalopram—Feeling abnormal—Prednisone—psoriasis	2.95e-05	7.51e-05	CcSEcCtD
Citalopram—Asthenia—Dexamethasone—psoriasis	2.95e-05	7.51e-05	CcSEcCtD
Citalopram—Asthenia—Betamethasone—psoriasis	2.95e-05	7.51e-05	CcSEcCtD
Citalopram—Nervous system disorder—Methotrexate—psoriasis	2.93e-05	7.47e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Methotrexate—psoriasis	2.93e-05	7.46e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Prednisone—psoriasis	2.93e-05	7.45e-05	CcSEcCtD
Citalopram—Nausea—Prednisolone—psoriasis	2.92e-05	7.45e-05	CcSEcCtD
Citalopram—Pruritus—Betamethasone—psoriasis	2.91e-05	7.4e-05	CcSEcCtD
Citalopram—Pruritus—Dexamethasone—psoriasis	2.91e-05	7.4e-05	CcSEcCtD
Citalopram—Skin disorder—Methotrexate—psoriasis	2.9e-05	7.4e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Methotrexate—psoriasis	2.89e-05	7.36e-05	CcSEcCtD
Citalopram—Vomiting—Triamcinolone—psoriasis	2.88e-05	7.33e-05	CcSEcCtD
Citalopram—CYP2C19—Metabolism—NDUFA5—psoriasis	2.87e-05	0.000865	CbGpPWpGaD
Citalopram—Nausea—Hydrocortisone—psoriasis	2.86e-05	7.27e-05	CcSEcCtD
Citalopram—Rash—Triamcinolone—psoriasis	2.86e-05	7.27e-05	CcSEcCtD
Citalopram—Dermatitis—Triamcinolone—psoriasis	2.85e-05	7.26e-05	CcSEcCtD
Citalopram—Anorexia—Methotrexate—psoriasis	2.85e-05	7.26e-05	CcSEcCtD
Citalopram—Urticaria—Prednisone—psoriasis	2.84e-05	7.24e-05	CcSEcCtD
Citalopram—Headache—Triamcinolone—psoriasis	2.84e-05	7.22e-05	CcSEcCtD
Citalopram—Abdominal pain—Prednisone—psoriasis	2.83e-05	7.2e-05	CcSEcCtD
Citalopram—Body temperature increased—Prednisone—psoriasis	2.83e-05	7.2e-05	CcSEcCtD
Citalopram—SLC6A4—Circadian rythm related genes—IL6—psoriasis	2.83e-05	0.000853	CbGpPWpGaD
Citalopram—Diarrhoea—Betamethasone—psoriasis	2.81e-05	7.16e-05	CcSEcCtD
Citalopram—Diarrhoea—Dexamethasone—psoriasis	2.81e-05	7.16e-05	CcSEcCtD
Citalopram—CHRM1—Circadian rythm related genes—JUN—psoriasis	2.8e-05	0.000845	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—TNF—psoriasis	2.8e-05	0.000845	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NDUFA5—psoriasis	2.8e-05	0.000844	CbGpPWpGaD
Citalopram—Hypotension—Methotrexate—psoriasis	2.79e-05	7.12e-05	CcSEcCtD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.78e-05	0.00084	CbGpPWpGaD
Citalopram—Musculoskeletal discomfort—Methotrexate—psoriasis	2.72e-05	6.94e-05	CcSEcCtD
Citalopram—Dizziness—Betamethasone—psoriasis	2.72e-05	6.92e-05	CcSEcCtD
Citalopram—Dizziness—Dexamethasone—psoriasis	2.72e-05	6.92e-05	CcSEcCtD
Citalopram—Insomnia—Methotrexate—psoriasis	2.7e-05	6.89e-05	CcSEcCtD
Citalopram—Nausea—Triamcinolone—psoriasis	2.69e-05	6.85e-05	CcSEcCtD
Citalopram—Paraesthesia—Methotrexate—psoriasis	2.69e-05	6.84e-05	CcSEcCtD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.67e-05	0.000807	CbGpPWpGaD
Citalopram—Dyspnoea—Methotrexate—psoriasis	2.67e-05	6.79e-05	CcSEcCtD
Citalopram—Somnolence—Methotrexate—psoriasis	2.66e-05	6.77e-05	CcSEcCtD
Citalopram—CYP2D6—Metabolism—NDUFA5—psoriasis	2.64e-05	0.000796	CbGpPWpGaD
Citalopram—Hypersensitivity—Prednisone—psoriasis	2.64e-05	6.71e-05	CcSEcCtD
Citalopram—Dyspepsia—Methotrexate—psoriasis	2.63e-05	6.7e-05	CcSEcCtD
Citalopram—Vomiting—Betamethasone—psoriasis	2.61e-05	6.65e-05	CcSEcCtD
Citalopram—Vomiting—Dexamethasone—psoriasis	2.61e-05	6.65e-05	CcSEcCtD
Citalopram—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.6e-05	0.000785	CbGpPWpGaD
Citalopram—Decreased appetite—Methotrexate—psoriasis	2.6e-05	6.62e-05	CcSEcCtD
Citalopram—Rash—Dexamethasone—psoriasis	2.59e-05	6.6e-05	CcSEcCtD
Citalopram—Rash—Betamethasone—psoriasis	2.59e-05	6.6e-05	CcSEcCtD
Citalopram—Dermatitis—Dexamethasone—psoriasis	2.59e-05	6.59e-05	CcSEcCtD
Citalopram—Dermatitis—Betamethasone—psoriasis	2.59e-05	6.59e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Methotrexate—psoriasis	2.58e-05	6.57e-05	CcSEcCtD
Citalopram—Fatigue—Methotrexate—psoriasis	2.58e-05	6.57e-05	CcSEcCtD
Citalopram—Headache—Dexamethasone—psoriasis	2.57e-05	6.55e-05	CcSEcCtD
Citalopram—Headache—Betamethasone—psoriasis	2.57e-05	6.55e-05	CcSEcCtD
Citalopram—Asthenia—Prednisone—psoriasis	2.57e-05	6.54e-05	CcSEcCtD
Citalopram—Pain—Methotrexate—psoriasis	2.56e-05	6.51e-05	CcSEcCtD
Citalopram—Pruritus—Prednisone—psoriasis	2.53e-05	6.45e-05	CcSEcCtD
Citalopram—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.48e-05	0.000749	CbGpPWpGaD
Citalopram—Feeling abnormal—Methotrexate—psoriasis	2.46e-05	6.28e-05	CcSEcCtD
Citalopram—Diarrhoea—Prednisone—psoriasis	2.45e-05	6.23e-05	CcSEcCtD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.45e-05	0.000738	CbGpPWpGaD
Citalopram—Gastrointestinal pain—Methotrexate—psoriasis	2.45e-05	6.23e-05	CcSEcCtD
Citalopram—Nausea—Dexamethasone—psoriasis	2.44e-05	6.21e-05	CcSEcCtD
Citalopram—Nausea—Betamethasone—psoriasis	2.44e-05	6.21e-05	CcSEcCtD
Citalopram—CYP2C19—Metabolism—CYP2S1—psoriasis	2.44e-05	0.000736	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP2S1—psoriasis	2.38e-05	0.000718	CbGpPWpGaD
Citalopram—Urticaria—Methotrexate—psoriasis	2.38e-05	6.05e-05	CcSEcCtD
Citalopram—Dizziness—Prednisone—psoriasis	2.37e-05	6.03e-05	CcSEcCtD
Citalopram—Abdominal pain—Methotrexate—psoriasis	2.36e-05	6.02e-05	CcSEcCtD
Citalopram—Body temperature increased—Methotrexate—psoriasis	2.36e-05	6.02e-05	CcSEcCtD
Citalopram—Vomiting—Prednisone—psoriasis	2.27e-05	5.79e-05	CcSEcCtD
Citalopram—Rash—Prednisone—psoriasis	2.26e-05	5.75e-05	CcSEcCtD
Citalopram—Dermatitis—Prednisone—psoriasis	2.25e-05	5.74e-05	CcSEcCtD
Citalopram—CYP2D6—Metabolism—CYP2S1—psoriasis	2.24e-05	0.000677	CbGpPWpGaD
Citalopram—Headache—Prednisone—psoriasis	2.24e-05	5.71e-05	CcSEcCtD
Citalopram—CYP1A2—Metabolism—NDUFA5—psoriasis	2.23e-05	0.000674	CbGpPWpGaD
Citalopram—Hypersensitivity—Methotrexate—psoriasis	2.2e-05	5.61e-05	CcSEcCtD
Citalopram—Asthenia—Methotrexate—psoriasis	2.15e-05	5.46e-05	CcSEcCtD
Citalopram—Nausea—Prednisone—psoriasis	2.13e-05	5.41e-05	CcSEcCtD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.12e-05	0.00064	CbGpPWpGaD
Citalopram—Pruritus—Methotrexate—psoriasis	2.12e-05	5.39e-05	CcSEcCtD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.11e-05	0.000638	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCL20—psoriasis	2.09e-05	0.000631	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.08e-05	0.000628	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.08e-05	0.000628	CbGpPWpGaD
Citalopram—Diarrhoea—Methotrexate—psoriasis	2.05e-05	5.21e-05	CcSEcCtD
Citalopram—Dizziness—Methotrexate—psoriasis	1.98e-05	5.04e-05	CcSEcCtD
Citalopram—Vomiting—Methotrexate—psoriasis	1.9e-05	4.84e-05	CcSEcCtD
Citalopram—CYP1A2—Metabolism—CYP2S1—psoriasis	1.9e-05	0.000573	CbGpPWpGaD
Citalopram—Rash—Methotrexate—psoriasis	1.89e-05	4.8e-05	CcSEcCtD
Citalopram—Dermatitis—Methotrexate—psoriasis	1.88e-05	4.8e-05	CcSEcCtD
Citalopram—Headache—Methotrexate—psoriasis	1.87e-05	4.77e-05	CcSEcCtD
Citalopram—HTR2C—GPCR ligand binding—CXCL8—psoriasis	1.86e-05	0.000562	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.86e-05	0.00056	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—TP53—psoriasis	1.85e-05	0.000558	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.84e-05	0.000557	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCL20—psoriasis	1.81e-05	0.000547	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCL20—psoriasis	1.81e-05	0.000545	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCL20—psoriasis	1.78e-05	0.000537	CbGpPWpGaD
Citalopram—Nausea—Methotrexate—psoriasis	1.78e-05	4.52e-05	CcSEcCtD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.78e-05	0.000536	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NDUFA5—psoriasis	1.72e-05	0.00052	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—IL6—psoriasis	1.69e-05	0.000511	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—CXCL8—psoriasis	1.61e-05	0.000487	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.61e-05	0.000486	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—CXCL8—psoriasis	1.61e-05	0.000486	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.61e-05	0.000485	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.6e-05	0.000484	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—CXCL8—psoriasis	1.58e-05	0.000478	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.58e-05	0.000476	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CARM1—psoriasis	1.58e-05	0.000475	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CARM1—psoriasis	1.54e-05	0.000466	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP2S1—psoriasis	1.47e-05	0.000442	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.38e-05	0.000417	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.28e-05	0.000385	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.22e-05	0.000367	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CARM1—psoriasis	1.19e-05	0.000359	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CARM1—psoriasis	1.16e-05	0.000351	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SOCS1—psoriasis	1.15e-05	0.000348	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.11e-05	0.000336	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—TYK2—psoriasis	1.1e-05	0.000331	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CARM1—psoriasis	1.09e-05	0.00033	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	1.05e-05	0.000318	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SOCS1—psoriasis	9.98e-06	0.000301	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.95e-06	0.0003	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SOCS1—psoriasis	9.95e-06	0.0003	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SOCS1—psoriasis	9.79e-06	0.000296	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CAT—psoriasis	9.69e-06	0.000292	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—CXCL8—psoriasis	9.56e-06	0.000289	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—TYK2—psoriasis	9.52e-06	0.000287	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CAT—psoriasis	9.49e-06	0.000286	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—TYK2—psoriasis	9.49e-06	0.000286	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—TYK2—psoriasis	9.34e-06	0.000282	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CARM1—psoriasis	9.28e-06	0.00028	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—CXCL8—psoriasis	9.12e-06	0.000275	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	9.09e-06	0.000274	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	8.95e-06	0.00027	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.67e-06	0.000262	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—APOE—psoriasis	8.5e-06	0.000256	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—LEP—psoriasis	8.5e-06	0.000256	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—CXCL8—psoriasis	8.29e-06	0.00025	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—CXCL8—psoriasis	8.26e-06	0.000249	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	8.13e-06	0.000245	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NFKBIA—psoriasis	7.92e-06	0.000239	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—APOE—psoriasis	7.53e-06	0.000227	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—APOE—psoriasis	7.37e-06	0.000223	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—LEP—psoriasis	7.37e-06	0.000222	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APOE—psoriasis	7.37e-06	0.000222	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APOE—psoriasis	7.34e-06	0.000222	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—LEP—psoriasis	7.34e-06	0.000222	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CAT—psoriasis	7.32e-06	0.000221	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APOE—psoriasis	7.23e-06	0.000218	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—LEP—psoriasis	7.23e-06	0.000218	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CARM1—psoriasis	7.16e-06	0.000216	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CAT—psoriasis	7.15e-06	0.000216	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NFKBIA—psoriasis	6.86e-06	0.000207	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NFKBIA—psoriasis	6.84e-06	0.000206	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CAT—psoriasis	6.73e-06	0.000203	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	6.73e-06	0.000203	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARG—psoriasis	6.56e-06	0.000198	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TYK2—psoriasis	6.49e-06	0.000196	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARG—psoriasis	6.42e-06	0.000194	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAT—psoriasis	5.71e-06	0.000172	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APOE—psoriasis	5.69e-06	0.000172	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—psoriasis	5.65e-06	0.00017	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TYK2—psoriasis	5.62e-06	0.00017	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TYK2—psoriasis	5.6e-06	0.000169	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APOE—psoriasis	5.55e-06	0.000168	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TYK2—psoriasis	5.52e-06	0.000166	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—psoriasis	5.37e-06	0.000162	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JUN—psoriasis	5.25e-06	0.000158	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APOE—psoriasis	5.23e-06	0.000158	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NFKB1—psoriasis	5.05e-06	0.000153	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARG—psoriasis	4.96e-06	0.00015	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—psoriasis	4.89e-06	0.000148	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—psoriasis	4.88e-06	0.000147	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARG—psoriasis	4.84e-06	0.000146	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—psoriasis	4.8e-06	0.000145	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—psoriasis	4.65e-06	0.00014	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—psoriasis	4.64e-06	0.00014	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—psoriasis	4.59e-06	0.000138	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—psoriasis	4.57e-06	0.000138	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARG—psoriasis	4.56e-06	0.000138	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JUN—psoriasis	4.55e-06	0.000137	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—psoriasis	4.54e-06	0.000137	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JUN—psoriasis	4.54e-06	0.000137	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JUN—psoriasis	4.47e-06	0.000135	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APOE—psoriasis	4.43e-06	0.000134	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAT—psoriasis	4.4e-06	0.000133	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NFKB1—psoriasis	4.38e-06	0.000132	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NFKB1—psoriasis	4.37e-06	0.000132	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NFKB1—psoriasis	4.3e-06	0.00013	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—psoriasis	3.98e-06	0.00012	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—psoriasis	3.96e-06	0.00012	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—psoriasis	3.94e-06	0.000119	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—psoriasis	3.92e-06	0.000118	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—psoriasis	3.9e-06	0.000118	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—psoriasis	3.86e-06	0.000117	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARG—psoriasis	3.86e-06	0.000117	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—psoriasis	3.47e-06	0.000105	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOE—psoriasis	3.42e-06	0.000103	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—psoriasis	3.17e-06	9.57e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—psoriasis	3e-06	9.06e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—psoriasis	2.99e-06	9.03e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARG—psoriasis	2.98e-06	8.99e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—psoriasis	2.95e-06	8.89e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—psoriasis	2.75e-06	8.3e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—psoriasis	2.74e-06	8.27e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—psoriasis	2.7e-06	8.14e-05	CbGpPWpGaD
